Quest Laboratories Ltd

Quest Laboratories Ltd

₹ 110 -1.79%
13 Dec - close price
About

Founded in June 1998, Quest Laboratories Limited produces a diverse range of pharmaceuticals, including antibiotics, antimalarials, anti-inflammatories, etc.[1]

Key Points

Product Profile[1] The company produces ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids.

  • Market Cap 180 Cr.
  • Current Price 110
  • High / Low 197 / 85.1
  • Stock P/E 15.3
  • Book Value 48.7
  • Dividend Yield 0.00 %
  • ROCE 57.5 %
  • ROE 46.1 %
  • Face Value 10.0

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 45.5%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Working capital days have increased from 46.3 days to 73.8 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Figures in Rs. Crores

Mar 2023 Sep 2023 Mar 2024 Sep 2024
39 41 42 43
36 32 35 31
Operating Profit 3 9 6 11
OPM % 9% 23% 15% 27%
0 0 0 1
Interest 0 0 0 0
Depreciation 0 0 0 0
Profit before tax 3 9 6 11
Tax % 26% 28% 33% 30%
2 6 4 8
EPS in Rs 3.16 4.89
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
30 59 62 83 84
29 53 54 67 67
Operating Profit 1 6 8 16 18
OPM % 5% 11% 13% 19% 21%
0 0 0 0 1
Interest 0 0 1 1 1
Depreciation 0 0 1 1 1
Profit before tax 1 6 7 14 17
Tax % 18% 29% 28% 30%
1 4 5 10 12
EPS in Rs 8.45 8.05
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 40%
TTM: 5%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 148%
TTM: 39%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 45%
Last Year: 46%

Balance Sheet

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 1 1 1 12 16
Reserves 5 9 14 17 63
3 3 4 5 10
9 22 28 26 23
Total Liabilities 18 35 47 59 113
6 7 10 10 11
CWIP 0 0 0 0 0
Investments 0 0 0 0 0
12 27 37 49 101
Total Assets 18 35 47 59 113

Cash Flows

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024
1 3 4 3
-1 -2 -4 -5
0 -0 0 2
Net Cash Flow -0 1 0 0

Ratios

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 110 135 118 104
Inventory Days 12 9 97 113
Days Payable 119 140 215 137
Cash Conversion Cycle 3 4 1 79
Working Capital Days 31 25 40 74
ROCE % 55% 47% 58%

Shareholding Pattern

Numbers in percentages

Sep 2024
65.83%
0.74%
4.44%
29.00%
No. of Shareholders 857

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents